Nitrite in Organ Protection by Rassaf T et al.
REVIEW
Nitrite in organ protection
Tienush Rassaf1, Peter Ferdinandy2,3 and Rainer Schulz4
1Department of Medicine, Division of Cardiology, Pulmonary and Vascular Medicine, University
Hospital Düsseldorf, Düsseldorf, Germany, 2Department of Pharmacology and Pharmacotherapy,
Semmelweis University, Budapest, Hungary, 3Pharmahungary Group, Szeged, Hungary, and
4Department of Physiology, Justus-Liebig-University, Giessen, Germany
Correspondence
Prof Dr Tienush Rassaf, Division
of Cardiology, Pulmonary and
Vascular Medicine, Medical
Faculty, University Hospital
Düsseldorf, Moorenstrasse 5,
D-40225 Düsseldorf, Germany.
E-mail: tienush.rassaf@med
.uni-duesseldorf.de
----------------------------------------------------------------
Commissioning Editor: Peter
Ferdinandy
----------------------------------------------------------------
Keywords
nitrite; nitric oxide
----------------------------------------------------------------
Received
4 April 2013
Revised
9 June 2013
Accepted
21 June 2013
In the last decade, the nitrate-nitrite-nitric oxide pathway has emerged to therapeutical importance. Modulation of
endogenous nitrate and nitrite levels with the subsequent S-nitros(yl)ation of the downstream signalling cascade open the
way for novel cytoprotective strategies. In the following, we summarize the actual literature and give a short overview on the
potential of nitrite in organ protection.
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oxide synthase; Mb, myoglobin; MPTP, mitochondrial permeability transition pore; Ng, neuroglobin; nNOS, NOS I,
neuronal nitric oxide synthase; XOR, xanthine oxidoreductase
Sources of nitrite
Three sources of nitrite have been identified in mammalian
physiology. The first, endogenous source is the oxidation of
the nitric oxide (NO) radical to nitrite. NO is produced endog-
enously from the amino-acid L-arginine by the NO-synthases
(NOSs). Three different NOSs exist: the endothelial NOS
(eNOS, NOS III), the inducible NOS (iNOS, NOS II) and the
neuronal NOS (nNOS, NOS I). The genes for the three differ-
ent NOS-isoforms are located on different chromosomes.
eNOS was first discovered in the vascular endothelium, nNOS
in the brain and iNOS in macrophages. Whereas eNOS
and nNOS are constitutively expressed in calcium and
calmodulin-dependent, transcription of iNOS is induced by
cytokines and lipopolysaccharides. The enzymatic produc-
tion of NO contains a five-electron transfer and requires
the presence of several substrates and cofactors, such as
L-arginine, oxygen, tetrahydrobiopterin and reduced nicoti-
namide adenine dinucleotide phosphate (for review see:
Moncada and Higgs, 1993). NO is a highly reactive gaseous
molecule with one unpaired electron. NO acts mainly in
auto/paracrine fashion, and signalling is limited by its rapid
oxidation to nitrite and nitrate, and its rapid non-enzymatic
reaction with superoxide to yield peroxynitrite (for review
see: Ferdinandy and Schulz, 2003). NO rapidly reacts with
oxyhaemoglobin to form methemoglobin and nitrate. Oxi-
dation of NO to nitrite is enhanced by the multicopper
oxidase ceruloplasmin, catalyzing the oxidation of NO to
NO+ which is rapidly hydrolyzed to nitrite (Shiva et al., 2006).
The second major source is nitrite reduced from nitrate
(Figure 1). Green leafy vegetables, such as lettuce, spinach
and beetroot all contain high concentrations of nitrate. One
serving of such a vegetable contains more nitrate than what
is endogenously formed by all three NOS isoforms during 1
day in humans (Lundberg et al., 2009). After ingestion of
nitrate and effective absorption in the upper gastrointestinal
tract, concentrations of nitrate in the saliva reach millimolar
concentrations. In the oral cavity, commensal anaerobic bac-
teria reduce nitrate to nitrite by their nitrate reductase
enzymes. When swallowed, due to the acidic gastric milieu,
part of the nitrite is immediately protoned to nitrous acid,
which then decomposes to NO and other nitrogen oxides.
Most of the swallowed nitrite escapes the acidic milieu and
enters the systemic circulation. Reduction of nitrate to nitrite
with the consecutive increase in circulating nitrite levels is
highly dependent on the oral commensal bacteria. Avoidance
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of swallowing (Lundberg and Govoni, 2004) and the use
of an antibacterial mouthwash (Hendgen-Cotta et al., 2012)
abolish the conversion of nitrate to nitrite and the consecu-
tive increase in plasma nitrite.
The third source is dietary ingestion of nitrite. Cured meat
contains nitrite which is used to protect from bacterial con-
tamination and to give the meat the fresh red colour. Fur-
thermore, baked goods, beets, corn and spinach are all major
sources of nitrite (Lundberg et al., 2009; van Faassen et al.,
2009).
Nitrite levels in mammals
All three above described sources contribute to the circulating
nitrite pool. Physical exercise, dietary habits, health status
and lifestyle lead to a variability in measured nitrite levels.
Plasma nitrite levels in healthy fasted humans range from
0.1 to 0.5 uM (Rassaf et al., 2002; 2003; 2006a; 2007a;
2010); lower levels of nitrite have been described in patients
with myocardial infarction and endothelial dysfunction
(Kehmeier et al., 2008), often as a result of hypertension and
diabetes mellitus (Fujiwara et al., 2000). Physical exercise
increases plasma nitrite levels in healthy subjects (Rassaf
et al., 2006b; 2007a), but not in patients with cardiovascular
disease and/or endothelial dysfunction (Rassaf et al., 2010).
Plasma nitrite levels may be lowered by about 50% by dietary
restrictions (Gladwin et al., 2000) and can be increased by
diet rich in nitrate (van Velzen et al., 2008; Heiss et al., 2012).
Nitrite levels in erythrocytes have been described to be higher
than in plasma (Bryan et al., 2004; Dejam et al., 2005). A
recent study investigating the NO-metabolism in Tibetan
highlanders – a population well adapted to environmental
hypoxia associated with high altitudes – revealed plasma
nitrite levels of about 10 uM, exceeding the plasma nitrite
levels of humans living at sea level 50-fold (Erzurum et al.,
2007). This high nitrite concentration was associated with
increased blood flow in this population. Circulating nitrite
levels in rodents are higher than those in normal humans
and have been described as high as 10 uM (Feelisch et al.,
2002; Rodriguez et al., 2003; Bryan et al., 2004), thereby
matching the levels seen in humans in high altitude. One
reason for the higher nitrite levels in rodents may be that
NO-synthase activity is several folds higher in mice compared
to humans (Wickman et al., 2003).
Toxic levels of nitrite and nitrate
The US Food and Drug Administration and the European
Food Safety Authority considered a dose of 22 mg sodium/
nitrite/kg as lethal for adults due to the complications that
arise from methemoglobinemia. Lower dosages apply for
infants, who are more susceptible and vulnerable than adults.
Figure 1
Sources for nitric oxide (NO) formation in mammals. NO is formed by the endothelial NOS (eNOS) using L-arginine as a substrate in an
oxygen-dependent manner. Dietary nitrate is reduced to nitrite via commensal bacteria in the oral cavity. Nitrite can be reduced to NO in eNOS
independently via deoxygenated myoglobin (Mb), haemoglobin (Hb), neuroglobin (Ng), xynthin oxidoreductase, protons, aldehyde oxidase and
enzymes of the respiratory chain to bioactive NO.
BJP T Rassaf et al.
2 British Journal of Pharmacology (2014) 171 1–11
A major health concern is also that dietary nitrite and nitrite
derived from dietary nitrate may lead to cancer, due to
a proposed association between nitrate intake and the
formation of the carcinogen substances N-nitrosamines
(Spiegelhalder et al., 1976). Nitrite – in contrast to nitrate –
undergoes nitrosative chemistry; this is prevented by ascorbic
acid and therefore nitrite added to meat products contains
supra-stoichiometric erythorbate or ascorbic acid. Experi-
mental and epidemiologic studies, however, failed to show an
increased risk of cancer with increasing consumption of
nitrate (van Loon et al., 1998; Pannala et al., 2003; Hord et al.,
2009; Tang et al., 2011) and the Joint Food and Agriculture
Organization/World Health Organization Expert Committee
on Food Additives concluded in 2003 that there was no
evidence that nitrate was carcinogenic in humans. Epidemio-
logical studies mostly indicate that abundant consumption of
vegetables reduce the risk of cancer (Block et al., 1992; Terry
et al., 2001). It should be noted that high doses of nitrite
preparations are widely used for acute care in cyanide poi-
soning (see for review: Gracia and Shepherd, 2004).
Bioactivation of nitrite
For many years nitrite has been regarded as an inert
by-product of the NO-pathway. However, experimental and
clinical studies over the past years challenged this dogma.
Several endogenous pathways exist that provide the reduc-
tion of nitrite to NO, with haemoglobin, myoglobin, neu-
roglobin, cytoglobin, xanthine oxidoreductase, eNOS and
mitochondrial enzymes being involved (for reviews see: van
Faassen et al. 2009; Lundberg et al., 2009). The extent of con-
tribution of the different pathways depends on the tissue, the
pH, oxygen tension and redox status (Feelisch et al., 2008).
Under normoxia, oxygenated haemoglobin rapidly reacts
with nitric oxide to form methemoglobin and nitrate.
Hypoxia, however, leads to an alteration of haemoglobin
conformation and oxygen binding status, affecting its ability
to reduce nitrite (Huang et al. 2005a,b). During rapid desoxy-
genation, nitrite reductase activity increases, reaching a peak
at pO2 (Jansson et al., 2008), that is the moment when 50% of
the haemoglobin is saturated with oxygen (Huang et al.,
2005b). Through this allosterically controlled bioactivation
of nitrite, erythrocytes possess a kind of oxygen sensor, which
may enable them to modulate microvascular flow by eliciting
nitrite-derived NO and vasodilation in areas of poor oxygena-
tion. Whereas the exact role of erythrocytes in the regulation
of vascular flow is still under debate, it was shown in a recent
study with myoglobin-deficient mice that vascular myoglo-
bin may be responsible at least in part for the regulation of
hypoxic vasodilation (Totzeck et al., 2012a). Myoglobin has
also been identified to play a role in cardiac nitrite bioactiva-
tion. Under normoxic conditions, oxymyoglobin protects the
heart from the deleterious effects of excessive NO (Godecke
et al., 2003). Under hypoxia, however, myoglobin changes its
role from an NO scavenger to an NO producer. Deoxymyo-
globin reduces nitrite to bioactive NO thereby leading to an
adaptation of cardiac energetics to myocardial function
under hypoxic and ischaemic conditions (Rassaf et al., 2007b;
Hendgen-Cotta et al., 2010a,b; Totzeck et al., 2012b).
In myocardial ischaemia/reperfusion, NO accumulation
by electron-spin-resonance spectroscopy has been shown
during ischaemia in spite of the lack of oxygen in rat hearts,
which has been suggested to be via a non-enzymatic mecha-
nism (Csonka et al., 1999; Zweier et al., 1999). Later it has
been shown that there are nitrite reductase activities in the
myocardium. In myocardial ischaemia/reperfusion injury,
myoglobin-mediated NO formation has been shown to be
cytoprotective and important for improvement of left ven-
tricular function after infarction (Hendgen-Cotta et al., 2008).
Other heme-proteins that elicit nitrite-reductace activity
under hypoxic conditions are neuroglobin and cytoglobin
(Petersen et al., 2008; Tiso et al., 2011; 2012). The relevance
and function of these nitrite-reductases have still to be
elucidated.
Another nitrite reductase is the xanthine oxidoreductase
(XOR), which fulfils its role in purine catabolism and gener-
ates the reactive oxygen species superoxide anions, hydroxyl
radicals and hydrogen peroxide. XOR, which is up-regulated
in ischaemia and inflammation (Harrison, 2004), reduces
inorganic nitrite (Godber et al., 2000) and nitrate (Jansson
et al., 2008) to NO.
eNOS itself has also been identified as a nitrite reductase
(Gautier et al., 2006; Vanin et al., 2007) under anoxia and
under acidic conditions. This function enables eNOS to
produce NO under both normoxic and hypoxic conditions.
Mitochondria are important targets for NO. NO binds to
the complexes of the respiratory chain and thus inhibits
respiration (Bolanos et al., 1994; Brown and Cooper, 1994;
Cleeter et al., 2001). Under hypoxia, however, several mito-
chondrial complexes like complex III, complex IV and
ubiquinone/cytochrome b1 can reduce nitrite (671; 672; 673).
Another mitochondrial enzyme which reduces nitrite to NO
is the aldehyde oxidase (Li et al., 2008).
Cytochrome P450, a family of enzymes which are
involved in drug metabolism, have been shown to exert
nitrite reductase activity (Kozlov et al., 2003). The physio-
logical relevance of this novel function is still under
investigation. Furthermore, the ubiquitous enzyme carbonic
anhydrase has been shown to generate NO from nitrite
(Aamand et al., 2009), which may be important for the regu-
lation between blood flow and metabolic activity in tissues.
Last but not least, in the stomach (Benjamin et al., 1994;
Lundberg et al., 1994) and under acidic conditions nitrite can
undergo protonation to nitric oxide (Zweier et al., 1995;
1999).
In summary, several pathways have been identified for
the reduction and thus bioactivation of nitrite to NO. In the
following, the relevance of the respective reactions in organ
protection will be discussed.
Nitrite in organ protection
As early as 1956, nitrite alone was demonstrated to protect
phages against X-ray radiation injury, presumably acting as a
reducing agent (Bachofer, 1956). Later on, the presence of
nitrite, but not nitrate, reduced the extent of apoptosis
in cultured endothelial cells during UVA-irradiation in a
concentration-dependent manner by inhibiting lipid peroxi-
dation; this protective effect was abolished by simultaneous
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administration of a NO scavenger (Suschek et al., 2003) sug-
gesting that nitrite-derived NO may contribute to protection
against UV-induced cell damage (Suschek et al., 2006). Nitrite,
generated from nitrate by oral bacteria ‘the so called entero-
salivary cycle’, and then converted to NO (Benjamin et al.,
1994; Lundberg et al., 1994; 2009; 2006; 2008; Kapil et al.,
2010a) in the stomach was also suggested to play an impor-
tant role in the protection of gastric mucosa from hazardous
stress (Miyoshi et al., 2003). Indeed, the stomach content, but
also the plasma, heart (Samouilov et al., 2007) and liver
nitrite levels were significantly reduced after dietary nitrate
and nitrite depletion (Feelisch et al., 2002), and could be
restored to normal levels with nitrite supplementation (Bryan
et al., 2007).
As mentioned above, dietary nitrate is an important
source of the endogenous nitrite pool, with vegetables being
the main source of nitrate in our diet. Epidemiologic studies
have demonstrated that diets rich in vegetables and fruits
(i.e. the Mediterranean diet) protect against cardiovascular
(Willett, 1994) diseases and first interventional trials have
demonstrated that such diets lower blood pressure (Liese
et al., 2009). Whereas the active compound being responsible
for this protection has not been identified so far, it is impor-
tant to note that high dietary nitrate concentrations reduce
blood pressure to a level similar to that achieved with a
Mediterranean diet.
Lundberg and Weitzberg were the first to describe a
blood pressure lowering effect of inorganic sodium nitrate
in healthy volunteers (Larsen et al., 2006). Diastolic blood
pressure was reduced by 4 mmHg after ingestion of a
sodium-nitrate drink compared to placebo. The authors sug-
gested that the formation of vasodilatory nitric oxide was
responsible for this effect. The results have been corrobo-
rated by other groups investigating the effects of beet root
juice – which contains high amounts of nitrate – on blood
pressure (Webb et al., 2008; Kapil et al., 2010b). In a recent
study, it has been demonstrated that nitrate has also
blood pressure lowering effects in humans with hyperten-
sion when applied in lower doses (Ghosh et al., 2013). In
further studies, Larsen et al. found that the oxygen cost
during standardized exercise was reduced after dietary
nitrate supplementation compared to placebo (Larsen et al.,
2007; Weitzberg et al., 2010). No differences in lactate
formation were measured, indicating that there was no
compensatory increase in glycolic energy contribution, and
thus metabolic efficiency seemed to be improved (Weitzberg
et al., 2010).
Applying the protocol of Larsen et al. (2006), the effects of
dietary nitrate supplementation on healthy subjects with
endothelial dysfunction was investigated; nitrate supplemen-
tation reversed endothelial dysfunction, an effect that
was associated with an increase in circulating vascular pro-
genitor cells (Heiss et al., 2012), endogenous nitrite and
S-nitrosothiol levels. In a mouse hind-limb model, dietary
nitrate improved vascular regeneration compared to placebo
(Hendgen-Cotta et al., 2012). The cytoprotective effects of
nitrate were completely abolished, however, when mice
received a mouthwash twice daily, using a commercially
available antibacterial solution that eradicated the commen-
sal bacterial flora which is necessary to reduce nitrate to
nitrite (Hendgen-Cotta et al., 2012).
Cardiovascular
Acidified sodium nitrite, a releaser of NO, reduced infarct size
(expressed as percentage of the area at risk) in a cat model of
90 min ischaemia and 270 min reperfusion when intrave-
nous infusion of acidified sodium nitrite was started 30 min
after coronary artery occlusion (Johnson et al., 1990).
Since the rate of NO generation from nitrite depends on
the reduction in oxygen and pH, nitrite could be reduced to
NO in ischaemic tissue and exert protective effects (for
review, see van Faassen et al., 2009). Therefore, sodium
nitrite (without acidification) was administered in mice
undergoing ischaemia/reperfusion and indeed nitrite reduced
myocardial infarct size by 67%. Consistent with hypoxia-
dependent nitrite bioactivation, nitrite was reduced to NO,
S-nitrosothiols, N-nitrosamines and iron-nitrosylated heme
proteins during early reperfusion (for review, see Tiravanti
et al., 2004). Nitrite-mediated protection was independent of
endothelial nitric oxide synthase (Webb et al., 2004; Duranski
et al., 2005). These findings were confirmed in rat hearts in
vitro and in vivo, which also demonstrated that intravenous
nitrate infusion – when given at the same dose as nitrite –
conferred no reduction in infarct size following ischaemia/
reperfusion (Baker et al., 2007). Bioactivation on nitrite
required increased activity of xanthine dehydrogenase and
xanthine oxidase during ischaemia in rats (Baker et al., 2007)
and the presence of myoglobin in mice (Rassaf et al., 2007b),
since the reduction in infarct size following administration of
nitrite was completely abolished in myoglobin knockout
mice (Hendgen-Cotta et al., 2008). However, more nitrite
reducing pathways are available under ischaemic/hypoxic
conditions (for review, see Dezfulian et al., 2007; Sinha et al.,
2008; Shiva et al., 2011; Tota et al., 2011). The mechanism
how nitrite exerts its cytoprotective effects has been described
earlier (Shiva et al., 2007); nitrite modifies and inhibits
complex I by post-translational S-nitrosation. This dampens
electron transfer and reduces reactive oxygen species genera-
tion and ameliorates oxidative inactivation of complexes
II–IV and aconitase. This prevents mitochondrial permeabil-
ity transition pore opening and cytochrome c release (Shiva
et al., 2007).
Another potential mechanism of nitrite-induced protec-
tion relates to the modification of the mitochondrial perme-
ability transition pore (MPTP) opening, which plays a critical
role in mediating cell death during ischaemia/reperfusion
injury. Cyclophilin D (Cyp D), which accelerates MPTP
opening, undergoes S-nitrosylation on cysteine 203 of Cyp D,
leading to reduced MPTP opening in mice wild-type fibro-
blast but not in Cyp D knockout fibroblast (Nguyen et al.,
2011). In our recent experiments, nitrite reduced infarct size
following ischaemia/reperfusion in wild-type mice but not in
Cyp D knockout mice suggesting that the above mechanism
might hold true also in hearts in vivo (Figure 2).
Also mice fed a standard diet with supplementation of
nitrite in their drinking water for 7 days exhibited signifi-
cantly higher plasma and myocardial levels of nitrite, nitroso
and nitrosyl–heme and displayed a 48% reduction in infarct
size following ischaemia/reperfusion. Supplemental nitrate in
the drinking water for 7 days also increased blood and tissue
NO products and significantly reduced infarct size (Bryan
et al., 2007). Nitrite supplementation in the drinking water
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for 1 week restored NO homeostasis also in eNOS knockout
mice, normally having reduced NO and NO metabolites, and
protected against ischaemia/reperfusion injury (Bryan et al.,
2008). In humans, endothelial dysfunction is also associated
with reduced circulating nitroso compounds (Heiss et al.,
2006) and the lack to increase plasma nitrite levels during
exercise (Lauer et al., 2008; Rassaf et al., 2010), the latter con-
tributing to protection of the heart against myocardial
ischaemia/reperfusion injury by exercise (Calvert et al., 2011)
(for review, see Calvert, 2011).
Cardioprotective signalling of nitrite in rats involved the
activation of NADPH oxidase and ATP-dependent potassium
channels (Baker et al., 2007). NO-dependent activation of
PKG through the soluble guanylate cyclase-cGMP pathway
has been shown to open mitochondrial ATP-dependent
potassium channels which results in a mild increase in reac-
tive oxygen species generation (Philipp et al., 2006), a modest
dose-dependent depolarization of the mitochondria, reduced
mitochondrial calcium accumulation and finally prevention
of the opening of the mitochondrial permeability transition
pore. Furthermore, nitrite affects cytochrome P450 activities,
heat shock protein 70 and heme oxygenase-1 expression in a
variety of tissues (Bryan et al., 2005).
In hyperlipidaemia, when NO bioavailability of the heart
is diminished possibly due to oxidative stress-induced forma-
tion of peroxynitrite (Onody et al., 2003; Csont et al., 2007),
NO-mediated cardioprotective pathways are disrupted (Giricz
et al., 2009; Kupai et al., 2009); (for reviews see Ferdinandy,
2003; Ferdinandy et al., 2007), and heat-shock protein 70
response is diminished (Csont et al., 2002). One could specu-
late that nitrite treatment to replenish NO formation in the
heart would be a plausible therapeutic option. This, however,
has not been investigated so far. In a clinical study by
Higashino et al. (2007), a male group of hypertensive patients
with complex co-morbidities of diabetes, hyperlipidaemia
and renal disorder had higher nitrate/nitrite levels compared
with a normotensive control group. This suggest that in
co-morbid states with oxidative stress, NO may be oxidized to
nitrite/nitrate. Whether nitrite treatment would reverse this
process and increase formation of cardiac NO is not known.
Nevertheless, it should be noted here that pathological
accumulation of NO in myocardial ischaemia may yield high
flux of non-enzymatic formation of peroxynitrite upon rep-
erfusion when there is a burst of superoxide generation. This
mechanism has been shown to contribute to reperfusion
injury of the heart (Yasmin et al., 1997; Csonka et al., 1999;
2001). Therefore, the protective or detrimental effect of NO
from whatever sources in ischaemia/reperfusion may largely
depend on the local concentrations NO and superoxide and
their ratio, if it favours formation of pathological concentra-
tions of peroxynitrite or not (see for reviews: Ferdinandy and
Schulz, 2003; Ferdinandy, 2006; Pacher et al., 2007). Whether
nitrite treatment may lead to pathological accumulation of
NO in the ischaemic myocardium is not known. However, it
may be a limitation of nitrite treatment in pathologies where
the non-enzymatic reaction of NO and superoxide yields
pathological concentrations of peroxynitrite.
EC barrier function and vessel response
Under hypoxic conditions, caspase-3 was de-nitrosylated
and the resulting activation of caspase-3 and subsequent
cleavage of β-catenin was critical for hypoxia-induced
increased endothelial permeability. Nitrite treatment led to
S-nitros(yl)ation and the inactivation of caspase-3, suppress-
ing the barrier dysfunction of endothelia caused by hypoxia.
This process required the conversion of nitrite to bioactive
nitric oxide in a nitrite reductase-dependent manner (Lai
et al., 2011). The supplementation of a low dose of nitrite
through local intra-arterial infusion, attenuated ischaemia-
reperfusion-induced vasoconstriction, arteriole stagnation,
and capillary no-reflow during reperfusion (Wang et al., 2011)
and prolonged application of nitrite improved revasculariza-
tion in chronically ischaemic peripheral muscles (Hendgen-
Cotta et al., 2012), potentially through mobilization of circu-
lating angiogenic cells (Heiss et al., 2012).
Brain
In a cerebral ischaemia/reperfusion injury model, using the
intraluminal occlusion of the middle cerebral artery for
90 min in rats, intravenous nitrite infusion at the time of
reperfusion reduced infarction volume (measured at 24 h)
and enhanced local cerebral blood flow and functional recov-
ery. Carboxy-PTIO, a direct NO scavenger, abolished the neu-
roprotective effects of nitrite (Jung et al., 2006). Varying the
time point of infusion further indicated that nitrite reduced
the infarction volume and enhanced functional recovery
when nitrite was administered within 3 h after transient
intraluminal occlusion and 1.5 h in the permanent occlusion
model in rats respectively (Jung et al., 2009). However, these
results were not confirmed in a study using intravenous
sodium nitrite as adjuvant to recombinant tissue plasmino-
gen activator in cerebral artery occlusion with 2 and 6 h of
ischaemia followed by reperfusion in rats. Nitrite treatment
did not reduce infarct volume at 48 h reperfusion compared
Figure 2
Blockade of mitochondrial permeability transition pore opening
reduces cytochrome c loss from the intermembrane space and pre-
vents apoptosis (for review see Schulz et al., 2004; Heusch et al.,
2008; Calvert and Lefer, 2009). Indeed, in our recent unpublished
experiments in anaesthetized mice nitrite reduced infarct size follow-
ing 30 min coronary occlusion and 120 min reperfusion in wild-type
mice (P < 0.05). This reduction in infarct size by nitrite was not seen
in cyclophilin D knockout mice.
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with saline-treated placebo groups receiving recombinant
tissue plasminogen activator only (Schatlo et al., 2008).
In cynomolgus macaques, subarachnoid haemorrhage-
induced vasospasm created via implantation of a blood clot
was reversed by intravenous nitrite infusion (27 vs. 46% in
vehicle) (Pluta et al., 2005; Fathi et al., 2011). Furthermore, a
single dose of intravenous nitrite given at cardiopulmonary
resuscitation improved cardiac function, survival and neu-
rological outcomes in a placebo-controlled study in a mouse
model of cardiac arrest (Dezfulian et al., 2009). When nitrite
was injected intravenously 3 h after intracerebral haemor-
rhage induction in rats, most doses of nitrite provided no
beneficial effect on behavioural deficits, brain oedema and
hematoma volumes. A high dose of nitrite, however, de-
creased hematoma volume, but not brain oedema (Jung
et al., 2011).
Thus, depending on the timing of application nitrite
might not only reduce irreversible brain injury following
ischaemia/reperfusion but also vasospasm following cerebral
haemorrhage.
Liver
In hepatic ischaemia/reperfusion injury in mice, nitrite
exerted profound dose-dependent protective effects on cellu-
lar necrosis and apoptosis, with highly significant protective
effects observed at near-physiological nitrite concentrations.
Nitrite-mediated protection of the liver was dependent on
NO generation and independent of endothelial NO synthase
and heme oxygenase-1 enzyme activities (Duranski et al.,
2005). In patients undergoing orthotopic liver transplanta-
tion, inhaled NO doubled plasma nitrite levels, which
improved liver function and reduced liver injury (Lang et al.,
2007). Although the authors stated that not all effects of
inhaled NO may be mediated by nitrite, it seems to be
obvious that protective effects of nitrite in ischaemia/
reperfusion injury may be translated into humans (Lang
et al., 2007).
Nitrite can also convey NO bioactivity in an endocrine
fashion. It can be transported in blood, metabolized in
remote organs (see above), and mediate cytoprotection in the
setting of ischaemia/reperfusion injury. Indeed, in mice with
cardiac-specific overexpression of the human endothelial NO
synthase gene nitrite, nitrate and nitrosothiols levels were
increased in the heart, plasma and liver. These mice displayed
a significant reduction in hepatic ischemia/reperfusion injury
compared with wild-type littermates (Elrod et al., 2008).
Finally, liver ischemia/reperfusion injury is a major cause
of primary graft non-function or initial function failure
post-transplantation. Liver enzyme release was significantly
reduced with nitrite supplementation, the protective effect
being more efficacious with longer cold preservation times.
Liver histological examination demonstrated better preserved
morphology, and less apoptosis with nitrite treatment and
liver graft acute function post-transplantation was improved
(Li et al., 2012).
Lung
In a mouse model of pulmonary arterial hypertension,
inhaled nebulized nitrite has been demonstrated to be a
potent pulmonary vasodilator that can effectively prevent or
reverse pulmonary arterial hypertension (Zuckerbraun et al.,
2011). Treatment with nebulized nitrite, either once or three
times per week prevented the development of pulmonary
arterial hypertension. Additionally, nitrite treatment 2 weeks
into the hypoxic exposure, after the establishment of pulmo-
nary hypertension, halted the progression of pulmonary
hypertension and reversed increases in right ventricular pres-
sure (Zuckerbraun et al., 2010; 2011). Further experimental
studies demonstrated that nitrite protects against ventilator-
induced lung injury in rats (Pickerodt et al., 2012).
Translation of those experimental results into the clinical
practise is ongoing. In an actual phase II trial (‘Inhaled nitrite
in subjects with pulmonary hypertension’, NCT01431313),
researchers from the University of Pittsburgh, PA, USA inves-
tigate the effects of inhaled nitrite delivered in a dose-
escalation manner on the change in pulmonary vascular
resistance in subjects with pulmonary arterial hypertension
undergoing right heart catheterization.
Kidney
In rats subjected to 60 min of bilateral renal ischaemia and
6 h of reperfusion sodium nitrite administered topically
1 min before reperfusion significantly attenuated renal dys-
function and injury, an effect that was abolished by pretreat-
ment with a NO scavenger. Renal tissue homogenates
produced NO from nitrite mainly through the activity of
xanthine oxidoreductase (Tripatara et al., 2007). Similarly, in
mice subjected to bilateral renal ischaemia for 30 min and
24 h reperfusion, renal dysfunction, damage and inflamma-
tion were increased; these effects were all reduced following
nitrite treatment 1 min prior to reperfusion. Within 1 min of
reperfusion kidney nitrite levels were raised. The beneficial
effects of nitrite were absent or reduced in mice deficient for
endothelial NO synthase and nitrite treatment under these
conditions even enhanced renal dysfunction (Milsom et al.,
2010).
Thus, sufficient metabolism of nitrite to NO appears to be
a prerequisite to obtain kidney protection. In rat kidney, NO
was generated from nitrite during following 40 min of ischae-
mia (which was independent from NO synthase activity and
thus differs from mice) (Okamoto et al., 2005). Not surpris-
ingly then that in male rats undergoing unilateral nephrec-
tomy followed by 45 min of ischaemia of the contralateral
kidney, nitrite infusion before or during ischaemia did not
attenuate the loss of brush border, the extent of tubular
necrosis or red blood cell extravasation 24 and 48 h after
acute renal injury. Interestingly, nitrate infusion appeared to
worsen renal injury (Basireddy et al., 2006). However, in rats
subjected to unilateral nephrectomy and chronic high-salt
diet, dietary nitrate prevented proteinuria and histological
signs of renal injury (Carlstrom et al., 2011). Moreover,
signs of cardiac hypertrophy and fibrosis were attenuated
(Carlstrom et al., 2011).
Crush syndrome and shock
Limb muscle compression and subsequent reperfusion are the
causative factors in developing a crush syndrome. In rats
subjected to bilateral hind limb compression for 5 h followed
by reperfusion for 0 to 6 h, nitrite administration reduced the
extent of rhabdomyolysis markers such as potassium, lactate
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dehydrogenase and creatine phosphokinase. Nitrite treat-
ment also reduced the inflammatory activities in muscle
and lung tissues, finally resulting in a dose-dependent
improvement of survival rate (Murata et al., 2012). Similarly,
in a mouse shock model induced by a lethal tumour
necrosis factor challenge, nitrite treatment significantly
attenuated hypothermia, mitochondrial damage, oxidative
stress and dysfunction, tissue infarction and mortality.
Nitrite-dependent improvement in symptoms was not asso-
ciated with inhibition of mitochondrial respiratory complex
activity, but was dependent on the soluble guanylate cyclase
system. Nitrite could also provide protection against toxicity
induced by Gram-negative lipopolysaccharide (Cauwels et al.,
2009) (for further review please see Cauwels and Brouckaert,
2011).
Taken together, the nitrate-nitrite-NO pathway appears to
play a crucial role in protecting the heart, vessel, brain,
kidney and lung against ischaemia/reperfusion injury. Nitrite
treatment may be advantageous in well-known NO deficient
states such as, for example hyperlipidaemia. Timing and dose
of nitrite application as well as the potential to convert nitrite
to NO in the tissue are important to obtain a reduction in
injury.
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